AstraZeneca Sues Andrx Over Toprol-XL Patent

Law360, New York (July 23, 2004, 12:00 AM EDT) -- Drug maker AstraZeneca has filed another lawsuit against Andrx for patent infringement related to Andrx’s plan to market a generic version of hypertension drug Toprol-XL.

The complaint, filed in the U.S. District Court for the District of Delaware, is the result of a Paragraph IV Certification letter submitted by Andrx to AstraZeneca concerning its intent to manufacture and sell Toprol-XL (metoprolol succinate) in the 25 mg dose form, AstraZeneca said.

Generics drug applicants must include with their abbreviated new drug applications (ANDAs) a statement addressing the...
To view the full article, register now.